You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • FRI0396 Type2 Anti-CD20 Antibodies do not Rapidly Internalise from the Surface of B Cells from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus and Lyse Them More Efficiently than Rituximab (Type 1 Anti-20Antibody)

Alerts

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. SLE, Sjögren's and APS - treatment
FRI0396 Type2 Anti-CD20 Antibodies do not Rapidly Internalise from the Surface of B Cells from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus and Lyse Them More Efficiently than Rituximab (Type 1 Anti-20Antibody)
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address